{
    "id": 2447,
    "fullName": "CBL Y371H",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "CBL Y371H lies within the linker region of the Cbl protein (PMID: 20622007). Y371H results in a loss of Cbl ubiquitin ligase activity, leading to activation of FLT3, AKT, and STAT5, and transformation of cultured cells when co-expressed with FLT3 or KIT (PMID: 23696637, PMID: 20622007).",
            "references": [
                {
                    "id": 3307,
                    "pubMedId": 20622007,
                    "title": "Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20622007"
                },
                {
                    "id": 966,
                    "pubMedId": 23696637,
                    "title": "CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23696637"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 867,
        "geneSymbol": "CBL",
        "terms": [
            "CBL",
            "C-CBL",
            "CBL2",
            "FRA11B",
            "NSLL",
            "RNF55"
        ]
    },
    "variant": "Y371H",
    "createDate": "10/23/2014",
    "updateDate": "07/22/2015",
    "referenceTranscriptCoordinates": {
        "id": 111491,
        "transcript": "NM_005188",
        "gDna": "chr11:g.119278181T>C",
        "cDna": "c.1111T>C",
        "protein": "p.Y371H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18009,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18011,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture, reduced leukemia burden and prolonged survival in animal models (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18007,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ayvakit (avapritinib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture with reduced potency compared to other kinase inhibitors (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited growth of transformed hematologic cells expressing CBL Y371H and wild-type FLT3 in culture (PMID: 31309543).",
            "molecularProfile": {
                "id": 32935,
                "profileName": "CBL Y371H FLT3 wild-type"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15938,
                    "pubMedId": 31309543,
                    "title": "Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31309543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xospata (gilteritinib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 2865,
                "therapyName": "Gilteritinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture, and inhibited leukemic growth and prolonged survival in cell line xenograft models expressing FLT3 and CBL Y371H (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 810,
                "therapyName": "Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Nexavar (sorafenib) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9495,
                "therapyName": "PRT062607 + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Quizartinib (AC220) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Quizartinib (AC220) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9496,
                "therapyName": "PRT062607 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PRT062607 to treatment with Rydapt (midostaurin) resulted in enhanced inhibition of proliferation of cells expressing wild-type FLT3 and CBL Y371H in culture (PMID: 31943762).",
            "molecularProfile": {
                "id": 35377,
                "profileName": "CBL Y371H FLT3 pos"
            },
            "therapy": {
                "id": 9494,
                "therapyName": "Midostaurin + PRT062607",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18094,
                    "pubMedId": 31943762,
                    "title": "The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31943762"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2329,
            "profileName": "CBL Y371H",
            "profileTreatmentApproaches": [
                {
                    "id": 6141,
                    "name": "FLT3 Inhibitor",
                    "profileName": "CBL Y371H"
                }
            ]
        },
        {
            "id": 32935,
            "profileName": "CBL Y371H FLT3 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35377,
            "profileName": "CBL Y371H FLT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 111492,
            "transcript": "XM_011543057",
            "gDna": "chr11:g.119278181T>C",
            "cDna": "c.1111T>C",
            "protein": "p.Y371H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 111491,
            "transcript": "NM_005188",
            "gDna": "chr11:g.119278181T>C",
            "cDna": "c.1111T>C",
            "protein": "p.Y371H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}